Browse the evidence

Semaglutide administration reduces visceral fat accumulation and improves glucose intolerance in obese mice by downregulating key lipogenic proteins (CD36, FABP5, ACSL, PLIN2) in epididymal white adipose tissue.

In this mouse study, semaglutide reduced fat mass by altering how fat cells store and process lipids, specifically by downregulating proteins like CD36 and PLIN2. This suggests that GLP-1 therapies may have direct peripheral effects on fat tissue metabolism, not just central appetite control. For humans, this supports the use of GLP-1 agonists for obesity management, though human dosing and response may vary.

Bupropion/naltrexone combination therapy has questionable cardiovascular safety and modest weight loss effects.

Bupropion/naltrexone is a combination medication that can lead to modest weight loss (4-5%). However, its cardiovascular safety is uncertain, and the trial was terminated early. It is not as effective or safe as newer GLP-1 agonists.

Semaglutide treatment (1 mg/week) in people with HIV and metabolic dysfunction-associated steatotic liver disease causes a significant decrease in psoas muscle volume (~9.3%) without causing a statistically significant decline in physical function (gait speed and chair rise tests).

If you are taking semaglutide for weight loss or liver health, expect to lose some muscle volume along with fat. This study suggests your physical function (like walking speed and ability to stand up) may not decline, but to be safe, incorporate resistance training into your routine to help preserve muscle mass and strength.

The effect of Tirzepatide on Fat-Free Mass (FFM) is inconclusive and uncertain, with evidence showing significant FFM loss that may be greater than or comparable to other anti-obesity drugs depending on the dose and study.

Current research does not provide a clear answer on whether Tirzepatide preserves muscle mass better than other weight loss strategies. Some studies indicate significant muscle loss occurs alongside fat loss, while others suggest it might be less severe than with other drugs. More research is needed to determine if specific dosing protects lean mass.

GLP-1 RAs show potential to slow the progression of neurodegenerative diseases, including Alzheimer's and Parkinson's, by reducing neuroinflammation and potentially acting as neuroprotective agents.

Research suggests GLP-1 medications may help protect against Alzheimer's and Parkinson's disease by reducing brain inflammation. While not yet a standard treatment for these conditions, ongoing clinical trials are investigating their use. If you have risk factors for cognitive decline, discussing these emerging benefits with your doctor may be relevant, especially if you are already using GLP-1s for diabetes or weight management.

Genetic predisposition to higher gut microbial butyrate production potential is causally linked to improved insulin response during an oral glucose tolerance test, while higher fecal propionate levels are causally linked to an increased risk of type 2 diabetes.

Your genetics influence how your gut bacteria process fiber into metabolites. While butyrate production is linked to better insulin response, high levels of propionate in stool have been causally linked to a higher risk of type 2 diabetes in genetic studies. This highlights the complexity of gut health beyond just 'eating fiber'.

The exponential decay of energy intake suppression during obesity pharmacotherapy is caused by a physiological proportional feedback control system that increases appetite in proportion to weight loss, rather than a diminishing direct effect of the drug itself.

If you are taking obesity medication and your weight loss slows down after a few months, it is likely due to your body's natural physiological resistance to losing weight, not necessarily because the drug has stopped working. This is a predictable part of the process described by proportional feedback control. Maintaining the medication as prescribed may still be beneficial for long-term weight management, even if the rate of loss decreases.

FGF21 is a liver-derived hormone that coordinates metabolic and behavioral responses to protein restriction and macronutrient imbalance, specifically driving changes in macronutrient choice.

This is a mechanistic insight. It suggests that the body has specific hormonal signals (like FGF21) that drive cravings for specific nutrients (like protein) when imbalanced. This explains why 'hunger' can be specific to certain foods, not just total calories.

GLP-1 receptor agonists may provide direct anti-inflammatory and disease-modifying benefits to osteoarthritic joints, independent of weight loss, by reducing pro-inflammatory cytokines and protecting chondrocytes.

Beyond helping you lose weight, GLP-1 medications might directly protect your knee joints from wear and tear. Research suggests these drugs can reduce inflammation within the joint itself and slow down cartilage loss, even independent of weight changes. This means you might experience less pain and slower progression of osteoarthritis, making these drugs a potentially dual-purpose treatment for both obesity and joint health.

OSH administration improves metabolic parameters, including glucose tolerance and insulin sensitivity, by increasing GLP-1 levels and protecting the intestinal barrier.

This study indicates that OSH may help regulate blood sugar and insulin levels in mice by boosting GLP-1. This is a potential benefit for metabolic health, but more research is needed to see if it applies to humans.

Semaglutide use is associated with acute kidney injury (AKI), specifically acute interstitial nephritis (AIN) and podocytopathies (FSGS/MCD), particularly in patients with pre-existing chronic kidney disease (CKD) or advanced age.

If you are taking semaglutide and notice swelling, changes in urination, or fatigue, report it to your doctor immediately, especially if you have existing kidney disease. Most cases of kidney injury from semaglutide are reversible if the drug is stopped early and treated with steroids.

Long-acting GLP-1 receptor agonist (Ex-4)2-Fc promotes adipose tissue browning and thermogenesis in high-fat diet mice by enriching gut Lactobacillus reuteri and reducing serum ceramide levels via upregulation of alkaline ceramidase 2 (Acer2).

This research suggests that GLP-1 agonists do more than just suppress appetite; they actively change how fat tissue works by promoting 'browning' (heat production) and improving lipid metabolism. This effect is linked to changes in gut bacteria (specifically Lactobacillus reuteri) and the reduction of harmful lipids called ceramides. For individuals considering GLP-1 therapy, this highlights that the drug works through complex biological pathways beyond just eating less, potentially offering metabolic benefits even at lower doses when combined with healthy gut flora.

Weight regain after discontinuation of GLP-1-based AOMs is an inherent feature of current pharmacological strategies, but future interventions such as gene therapy (GLP-1PGTx) or gradual dose-tapering may mitigate this by sustaining hormonal signals or allowing hormonal adaptation.

Stopping GLP-1 medications currently leads to weight regain for most people due to hormonal adaptations. While lifestyle changes help, they may not be enough to counteract these hormonal shifts. Future treatments, such as gene therapy or careful dose-tapering, aim to sustain weight loss after stopping, but these are not yet standard care. Patients should plan for long-term management strategies with their providers.

Combined GIPR/GLP1R agonism reduces systemic low-grade inflammation, evidenced by lower hepatic inflammatory markers and circulating adhesion molecules (ICAM-1, VCAM-1).

Dual GIP/GLP-1 therapy may help reduce chronic, low-grade inflammation associated with obesity and cardiovascular risk. This anti-inflammatory effect is part of the mechanism by which these drugs may protect blood vessels.

GLP-1 receptor agonists (GLP-1RAs) exert neuroprotective effects in neurodegenerative diseases (Alzheimer's, Parkinson's, Multiple Sclerosis) by modulating synaptic plasticity, reducing neuroinflammation, and promoting neurogenesis, although clinical trial outcomes remain variable.

GLP-1 drugs like semaglutide and liraglutide show promise in protecting brain cells and slowing cognitive/motor decline in diseases like Alzheimer's and Parkinson's, based on strong lab studies. However, human trials have been mixed, likely due to how patients are chosen and how trials are run. If you have a neurodegenerative condition, discuss with your doctor whether the potential brain benefits outweigh the risk of stomach side effects, especially if you are frail or elderly.

Novel GLP-1 receptor agonists (e.g., NLY01, tirzepatide) are being developed to enhance central nervous system penetration and efficacy, with some showing specific benefits in younger patient subgroups.

Newer GLP-1 drugs like NLY01 and tirzepatide are being designed to work better in the brain. Early results suggest they might help younger patients more than older ones. If you are interested in these treatments, ask your doctor about the latest clinical trials and whether a newer agent might be suitable for your specific condition and age.

Higher expression of the adipose (adp/WDTC1) gene in human subcutaneous adipose tissue is associated with lower body fat mass and enhanced insulin sensitivity.

This research identifies a specific gene (adp/WDTC1) in fat tissue that correlates with being leaner and more insulin sensitive. While you cannot directly 'dose' this gene, understanding that higher expression is linked to better metabolic health may inform future therapeutic targets for obesity and diabetes management.

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a statistically significant increase in the dispensing of antidepressants, suggesting a potential adverse effect on mood or mental health.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that there is a statistically higher chance you might be prescribed an antidepressant. This does not mean everyone will experience mood issues, but it is a known risk signal. Monitor your mental health closely, especially if you have a history of depression, and discuss any mood changes with your doctor immediately.

AMPK activation suppresses leptin secretion in adipocytes independently of adipogenesis and adipocyte maturity, challenging the view that AMPK's primary benefit is promoting adipose expansion.

While exercise and certain drugs activate AMPK to help store fat healthily, this research highlights that AMPK also directly reduces leptin, a hormone that tells your brain you're full. In obesity, high leptin levels cause resistance. By suppressing leptin secretion, AMPK activation might help restore the body's natural ability to feel full, offering a pathway to treat leptin resistance without just focusing on fat storage.

Semaglutide is associated with a statistically significant signal of disproportionate reporting for depressive disorders in real-world pharmacovigilance data, whereas liraglutide and tirzepatide show no such signal.

If you are taking semaglutide, be aware that real-world data shows a higher reporting rate of depression compared to other GLP-1RAs like liraglutide or tirzepatide. This does not mean the drug definitely causes depression, but it suggests you should monitor your mood, especially if you are female. Discuss any mood changes with your doctor, as they may consider drug-specific monitoring.

Long-term use of GLP-1 receptor agonists (specifically liraglutide, dulaglutide, and exenatide) is associated with an increased risk of thyroid tumors, including C-cell hyperplasia and medullary thyroid carcinoma, primarily through the stimulation of GLP-1 receptors on thyroid C cells leading to calcitonin gene expression and cellular hyperplasia.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza), your doctor should monitor your thyroid health, specifically checking calcitonin levels and potentially performing ultrasounds if you have symptoms or risk factors. This is because these drugs stimulate thyroid C-cells, which can lead to hyperplasia in animal models. While human risk is debated, caution is advised, especially if you have a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 (MEN2).

GLP-1 receptor agonists may increase the risk of acute pancreatitis and pancreatic cancer, although meta-analyses have sometimes excluded this risk, and the evidence remains inconclusive with conflicting study results.

Be aware of symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) while on GLP-1 medications. While the absolute risk is debated, it is a known potential side effect. Report any persistent abdominal pain to your doctor immediately.

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide) are associated with statistically significant signals for otolaryngologic adverse events, specifically GERD, Medullary Thyroid Carcinoma (MTC), and Papillary Thyroid Carcinoma (PTC), across all approved drugs.

If you take a GLP-1 drug like Ozempic or Wegovy, be aware that reports of acid reflux (GERD) and thyroid issues (MTC/PTC) are significantly higher than background noise in the FDA database. You should discuss these risks with your doctor and monitor for symptoms like persistent heartburn or neck lumps, but do not stop medication without medical advice.

Semaglutide and Liraglutide show significant signals for specific otolaryngologic adverse events including anosmia, dysgeusia, Bell's palsy, and tinnitus, which are not as strongly or consistently reported with other GLP-1 RAs.

If you take Semaglutide or Liraglutide and experience loss of smell, taste changes, ringing in the ears, or facial weakness (Bell's palsy), these are reported side effects. Inform your healthcare provider, as these may require management adjustments.